

Memo

To: User of Circular of Information
From: Christine Driscoll, Director, Regulatory Affairs and
Donna Strauss, Vice President, Laboratories

Date: February 13, 2020

Re: Circular of Information Update

In accordance with Food and Drug Administration (FDA) Guidance for Industry: Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis Guidance for Industry, May 2019, New York Blood Center is providing an update to the Babesia language.

The following information is to be considered a part of the Circular of Information as it applies to the *General Information for Whole Blood and All Blood Components, Testing of Donor Blood* section.

A licensed nucleic acid test (NAT) for Babesia has been performed and found to be nonreactive.